Gain Therapeutics Inc

GANX

Company Profile

  • Business description

    Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

  • Contact

    4800 Montgomery Lane
    Suite 220
    BethesdaMD20814
    USA

    T: +1 301 500-1556

    https://www.gaintherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    25

Stocks News & Analysis

stocks

Lower fair value on ASX best idea

Shares are still undervalued despite drop in profit margins.
stocks

We raise our near-term gold price assumptions

Our coverage remains overvalued.
stocks

Apple: Gemini partnership lets AI-worried investors breathe a sigh of relief

We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,161.5050.00-0.54%
CAC 408,330.9716.23-0.19%
DAX 4025,286.24134.42-0.53%
Dow JONES (US)49,149.6342.36-0.09%
FTSE 10010,184.3547.000.46%
HKSE26,882.22117.59-0.44%
NASDAQ23,471.75238.13-1.00%
Nikkei 22553,785.25555.98-1.02%
NZX 50 Index13,659.5298.19-0.71%
S&P 5006,926.6037.14-0.53%
S&P/ASX 2008,837.3043.70-0.49%
SSE Composite Index4,101.5224.57-0.60%

Market Movers